Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 7—July 2018
Research

Global Distribution of Human Protoparvoviruses

Elina Väisänen, Ushanandini Mohanraj, Paula M. Kinnunen1, Pikka Jokelainen, Haider Al-Hello, Ali M. Barakat, Mohammadreza Sadeghi2, Farid A. Jalilian, Amir Majlesi, Moses Masika, Dufton Mwaengo, Omu Anzala, Eric Delwart, Olli Vapalahti, Klaus Hedman, and Maria Söderlund-VenermoComments to Author 
Author affiliations: University of Helsinki, Helsinki, Finland (E. Väisänen, U. Mohanraj, P.M. Kinnunen, P. Jokelainen, O. Vapalahti, K. Hedman, M. Söderlund-Venermo); Statens Serum Institut, Copenhagen, Denmark (P. Jokelainen); Estonian University of Life Sciences, Tartu, Estonia (P. Jokelainen); National Institute for Health and Welfare, Helsinki (H. Al-Hello); Al-Hussein Teaching Hospital, Thi-Qar Governorate, Iraq (A.M. Barakat); Blood Systems Research Institute, San Francisco, California, USA (M. Sadeghi, E. Delwart); University of California, San Francisco (M. Sadeghi, E. Delwart); Hamadan University of Medical Sciences, Hamadan, Iran (F.A. Jalilian, A. Majlesi); University of Nairobi, Nairobi, Kenya (M. Masika, D. Mwaengo, O. Anzala); Helsinki University Hospital, Helsinki (O. Vapalahti, K. Hedman)

Main Article

Table 2

Seroprevalence of IgG against protoparvoviruses in different population cohorts*

Cohort No. persons Any bufavirus IgG† IgG against bufavirus genotypes
 Tusavirus IgG Cutavirus IgG‡
1 2‡ 3
Finland, healthy adults (veterinarians) 324 6 (1.9) 4 (1.2) 1 (0.3)§ 1 (0.3) 0 16 (4.9)§
United States, healthy adults 84 3 (3.6) 0 0 3 (3.6) 0 0
Iraq, healthy adults 99 84 (84.8) 80 (80.8) 33 (33.3)¶ 15 (15.2) 0 1 (1.0)¶
Iran, healthy adults 107 60 (56.1) 55 (51.4) 17 (17.9) 6 (5.6) 0 6 (5.6)
Kenya, febrile children <18 y of age 107 22 (20.6) 3 (2.8) 4 (3.7) 20 (18.7) 0 2 (1.9)
Kenya, febrile adults 119 86 (72.3) 31 (26.1) 43 (36.1)# 56 (47.1) 0 5 (4.2)#

*Values are no. (%) unless otherwise noted..
†Includes persons that were IgG+ against >1 bufavirus genotypes.
‡Unclear bufavirus 2 and cutavirus blocking results were observed for 1§ (0.3%), 2¶ (2.0%), and 3# (2.5%) persons. These values are not included in overall seroprevalence calculations.

Main Article

1Current affiliation: Finnish Food Safety Authority Evira, Helsinki, Finland.

2Current affiliation: University of Turku, Turku, Finland.

Page created: June 18, 2018
Page updated: June 18, 2018
Page reviewed: June 18, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external